The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 18, 2023
Filed:
Aug. 20, 2020
Applicant:
Emory University, Atlanta, GA (US);
Inventors:
Raymond F. Schinazi, Miami, FL (US);
Sebastien Boucle, Smyrna, GA (US);
Franck Amblard, Atlanta, GA (US);
Ozkan Sari, Decatur, GA (US);
Leda Bassit, Smyrna, GA (US);
Assignee:
Emory University, Atlanta, GA (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4025 (2006.01); A61K 31/454 (2006.01); A61K 31/427 (2006.01); A61K 31/4192 (2006.01); A61P 31/20 (2006.01); C07D 207/34 (2006.01); C07D 249/04 (2006.01); C07D 401/12 (2006.01); C07D 403/12 (2006.01); A61K 45/06 (2006.01); C07D 417/12 (2006.01); A61K 31/40 (2006.01); A61K 31/41 (2006.01); A61K 31/4178 (2006.01); A61K 31/4184 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); C07D 207/36 (2006.01); C07D 401/06 (2006.01); C07D 403/06 (2006.01);
U.S. Cl.
CPC ...
C07D 207/34 (2013.01); A61K 31/40 (2013.01); A61K 31/41 (2013.01); A61K 31/4178 (2013.01); A61K 31/4184 (2013.01); A61K 31/4192 (2013.01); A61K 31/427 (2013.01); A61K 31/454 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); A61P 31/20 (2018.01); C07D 207/36 (2013.01); C07D 249/04 (2013.01); C07D 401/06 (2013.01); C07D 401/12 (2013.01); C07D 403/06 (2013.01); C07D 403/12 (2013.01); C07D 417/12 (2013.01);
Abstract
The present invention is directed to compounds, compositions and methods for preventing, treating or curing Hepatitis B (HBV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment, prevention or eradication of HBV infection.